References
- Timeline of WHO’s response to COVID-19. 2020; Available from: https://www.who.int/news-room/detail/29-06-2020-covidtimeline.
- Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. Jama. 2020;323(13):1239–1242.
- WHO coronavirus disease (COVID-19) dashboard. 2020; Available from: https://covid19.who.int.
- Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–1098. .
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. .
- Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120–128. .
- Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–2610. .
- Negrini S, Pappalardo F, Murdaca G, et al. The antiphospholipid syndrome: from pathophysiology to treatment. Clin Exp Med. 2017;17(3):257–267. .
- Joshi A, Hong J, Siva C. Recurrent thrombosis in patients with antiphospholipid syndrome receiving newer oral anticoagulants: a case report and review of literature. Clin Med Res. 2017;15(1–2):41–44.
- Foerster KI, Hermann S, Mikus G, et al. Drug-drug interactions with direct oral anticoagulants. Clin Pharmacokinet. 2020;59(8):967–980. .
- Testa S, Prandoni P, Paoletti O, et al. Direct oral anticoagulant plasma levels’ striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience. J Thromb Haemost. 2020;18(6):1320–1323. .
- Testa S, Legnani C, Antonucci E, et al. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost. 2019;17(7):1064–1072. .
- Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum. Am J Hematol. 2019;94(6):697–709. .
- Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020;158(3):1143–1163. .
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. .
- Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):p. p. 844–847. .
- Hematology recommendations and dosing guidelines during COVID-19. 2020. Available from: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/guidance-from-mass-general-hematology.pdf.
- Antithrombotic therapy in patients with COVID-19. 2020. Available from: https://www.covid19treatmentguidelines.nih.gov/adjunctive-therapy/antithrombotic-therapy/.